Clover Health Investments, Corp. (CLOV) SEC Filings & Earnings Calls
EquiReason read 23 Clover Health Investments, Corp. SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
9 Oct 20268-K · 7.01CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non-SNP PPO plans.open
Figures in the filing · each found in the filing text
| Medicare Advantage membership · H1-2026 | 157,000 | +48% y/y |
| HEDIS score · 2027 | $4.82 |
Risks flagged
Ongoing litigation with CMS over Star rating calculation methodology; if appeal reverses, PPO rating could drop to 4.5 Stars
“CMS calculated rating removing 20 measures per court decision; with those measures included, PPO would have received 4.5 Stars; case is on appeal”
20 Aug 20268-K · 7.01Insurance Gross Profit PMPM Year 3 vs Year 1 $155.00; MCR Improvement CA-Managed vs Non-CA Year 3 18; CKD Diagnosis Earlier with CA 18open
Figures in the filing · each found in the filing text
| Insurance Gross Profit PMPM Year 3 vs Year 1 | $155.00 | |
| MCR Improvement CA-Managed vs Non-CA Year 3 | 18.0% | |
| CKD Diagnosis Earlier with CA | $18.00 | |
| Kidney Function Decline Slowing with CA | 72.0% |
Risks flagged
Operating expense ratio currently higher than peers due to deliberate investments; expected to improve with scale.
“Operating expense ratio higher than peers; company views this as temporary and expects operating leverage over time.”
7 Aug 202610-QClover Health reported strong Q2 2026 results with revenue up 56% YoY, net income of $28M vs loss in prior year, and improved margins.open
Figures in the filing · each found in the filing text
| Total revenues · Consolidated · Q2-2026 | $743M | +56% y/y |
| Total revenues · Consolidated · H1-2026 | $1.49B | +59% y/y |
| Net income (loss) · Consolidated · Q2-2026 | $28M | |
| Net income (loss) · Consolidated · H1-2026 | $55M | |
| Adjusted EBITDA · Consolidated · Q2-2026 | $41M | +139% y/y |
| Adjusted EBITDA · Consolidated · H1-2026 | $81M | +89% y/y |
| Average Medicare Advantage membership · Insurance · Q2-2026 | 156,840 | +49% y/y |
| Insurance Benefits Expense Ratio · Insurance · Q2-2026 | 87.6% | |
| Cash, cash equivalents, and investments · Consolidated · 2026-06-30 | $443M |
Risks flagged
CMS Star Ratings litigation risk
“On July 21, 2026, CMS filed its Notice of Appeal of the district court's decision in the Stars Litigation with the United States Court of Appeals for the Eleventh Circuit.” · word for word
Interest rate sensitivity on investment income
“Other income decreased by $2.4 million, or 31%, to $5.4 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease was primarily driven by ... lower investment income resulting from a lower interest rate environment, to which our returns are closely correlated given the short-duration nature of our invest” · word for word
5 Aug 20268-K · 2.02Total revenues $743M (+56% y/y); Consolidated Gross Profit $153M (+54% y/y); Net income (loss) $28M; Guidance: Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35Mearningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q2-2026 | $743M | +56% y/y |
| Consolidated Gross Profit · Q2-2026 | $153M | +54% y/y |
| Net income (loss) · Q2-2026 | $28M | |
| Adjusted EBITDA · Q2-2026 | $41M | +139% y/y |
| Average Medicare Advantage membership · Insurance · Q2-2026 | 156,840 | +49% y/y |
| Insurance BER · Insurance · Q2-2026 | 87.6% | |
| Total cash, cash equivalents, and investments · Q2-2026 | $443M | +14% y/y |
Guidance
Revenue raised to $2.92B-$3.00B; Gross Profit to $525M-$555M; Adjusted EBITDA to $70M-$85M; GAAP Net Income to $20M-$35M
Full-year guidance raised across all metrics, reflecting strong Q2 performance and confidence in 2027.
Risks flagged
Elevated cost trends and macro headwinds could impact future performance; reliance on Medicare Advantage star ratings.
“Company maintains cautious view for remainder of year in light of continued elevated cost trends and potential for macro headwinds.”
17 Jul 20268-K · 8.01Clover Health detects anomalous login activity; social engineering attack on three employee accounts; PHI/PII potentially accessed; no material impact expected.open
Risks flagged
Cybersecurity incident: social engineering attack on three employee accounts with access to member PII/PHI.
“a threat actor gained access to three non-managerial health plan employee accounts through social engineering... had access to certain personally identifiable information and protected health information” · word for word
Potential regulatory investigations and litigation from the incident.
“the outcome of any regulatory investigations or litigation” · word for word
18 May 20268-K · 7.01MCR improvement after first year 8; MCR improvement by year four 20; Clover Care Services enrollment growth 90open
Figures in the filing · each found in the filing text
| MCR improvement after first year · Clover Assistant cohort · Q1-2026 | 8.0% | |
| MCR improvement by year four · Clover Assistant cohort · Q1-2026 | 20.0% | |
| Clover Care Services enrollment growth · Clover Care Services · Q1-2026 | 90.0% |
Guidance
No formal guidance change; management reaffirms full-year focus and will reassess after Q2. Positive tone on cohort margin expansion and enrollment growth.
Risks flagged
Seasonality in medical costs could lead to earnings variability within the year, though managed on full-year basis.
“gross profit is typically stronger in the first half of the year, with costs building as the year progresses” · word for word
IRA-related changes to Part D seasonality may introduce additional uncertainty.
“IRA-related changes to Part D seasonality that began in 2025” · word for word
8 May 202610-QTotal revenues $749M (+62% y/y); Net income $27M; Adjusted EBITDA $40M (+56% y/y)open
Figures in the filing · each found in the filing text
| Total revenues · Q1-2026 | $749M | +62% y/y |
| Net income · Q1-2026 | $27M | |
| Adjusted EBITDA · Q1-2026 | $40M | +56% y/y |
| Average Medicare Advantage membership · Q1-2026 | 154,607 | +52% y/y |
| Premiums earned, net · Q1-2026 | $744M | +63% y/y |
| Insurance Benefits Expense Ratio · Q1-2026 | 86.5% | |
| Operating cash flow · Q1-2026 | $108M | |
| Free cash flow · Q1-2026 | $103M | |
| Adjusted SG&A · Q1-2026 | $119M | +44% y/y |
| Adjusted Net income · Q1-2026 | $40M | +57% y/y |
Risks flagged
Medical Cost Ratio Pressure
“Insurance Benefits Expense Ratio 86.5 % vs 86.1 %, an increase of 40 basis points” · word for word
Regulatory Dependency
“We earn premiums through our plans offered under contracts with CMS.” · word for word
Star Rating Risk
“we are currently being paid on 4.0 stars in the current year as compared to 3.5 stars in the prior period” · word for word
6 May 20268-K · 2.02Total revenues $749M (+62% y/y); Consolidated Gross profit $160M (+46% y/y); Net income (loss) $27M; Guidance: FY2026 revenue $2.81B-$2.92B (midpoint $2.865B, +49% YoY); Gross profit $470M-$510M; Adj EBITDA $50M-$70M; GAAP Net Income $0M-$2earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Consolidated · Q1-2026 | $749M | +62% y/y |
| Consolidated Gross profit · Consolidated · Q1-2026 | $160M | +47% y/y |
| Net income (loss) · Consolidated · Q1-2026 | $27M | |
| Adjusted EBITDA · Consolidated · Q1-2026 | $40M | +56% y/y |
| Average Medicare Advantage membership · Insurance · Q1-2026 | 154,607 | +52% y/y |
| Insurance revenue · Insurance · Q1-2026 | $744M | +63% y/y |
| Insurance BER · Insurance · Q1-2026 | 86.5% | |
| Total cash, cash equivalents, and investments · Consolidated · Q1-2026 | $418M | +7% y/y |
| Adjusted Net income · Consolidated · Q1-2026 | $40M | +57% y/y |
| Adjusted SG&A · Consolidated · Q1-2026 | $119M | +44% y/y |
Guidance
FY2026 revenue $2.81B-$2.92B (midpoint $2.865B, +49% YoY); Gross profit $470M-$510M; Adj EBITDA $50M-$70M; GAAP Net Income $0M-$20M
Management raised full-year guidance across all metrics, expecting first full year of GAAP net income profitability.
Risks flagged
Insurance BER increased slightly to 86.5% from 86.1%, indicating potential medical cost pressure.
“Insurance BER 86.5% vs 86.1% prior year, up 40 bps”
28 Apr 2026DEF 14AAnnual proxy statement filed; no material event.open
Figures in the filing · each found in the filing text
| Net Income (Loss) · FY2025 | $-86M | |
| Star Rating · FY2025 | $3.50 | |
| Total Shareholder Return (TSR) · FY2025 | $14.67 |
Risks flagged
Stars rating dependency
“in light of only achieving a 3.5 Stars rating, which triggered a cutback that reduced the 2025 overall bonus achievement level by 50%, determined that no bonuses would be paid to the NEOs in respect of the 2025 annual bonus period.” · word for word
Related party concentration
“Expenses and fees incurred related to these contracts, recorded in net medical claims incurred, were $4.4 million for the year ended December 31, 2025. ... Expenses and fees incurred related to this agreement was $1.5 million for the year ended December 31, 2025. ... Expenses and fees incurred related to this agreement was $8.3 million for the year ended Dec” · word for word
1 Apr 20268-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Leadership change could introduce uncertainty in strategy execution.
“Departure of a director or principal officer.”
27 Feb 202610-KStar Rating - PPO 3.5; Star Rating - HMO 4open
Figures in the filing · each found in the filing text
| Star Rating - PPO · PPO · 2026 | 3.5 | |
| Star Rating - HMO · HMO · 2026 | 4 |
Risks flagged
Medicare Advantage funding risk
“We derive substantially all of our Total revenues from Medicare Advantage premiums and expect to continue to derive a substantial portion of our Total revenues in the future from Medicare Advantage premiums.” · word for word
DOJ investigation / FCA risk
“As previously disclosed, we have received an inquiry from the U.S. Department of Justice ("DOJ")” · word for word
FDA regulation of Clover Assistant
“If the FDA determines that any of our current or future analytics applications, including Clover Assistant, are regulated as medical devices, we would become subject to various requirements under the FDCA and the FDA's implementing regulations.” · word for word
Star Rating dependency
“Failure to maintain satisfactory quality and performance measures may negatively affect our premium rates, subject us to penalties, limit or reduce our number of members.” · word for word
Change Healthcare breach impact
“In 2024, one of our vendors, UnitedHealth Group's Change Healthcare, experienced a ransomware attack, which compromised certain of our members' personal information (including protected health information).” · word for word
26 Feb 20268-K · 2.02Consolidated Gross Profit $356M (-2% y/y); Net Loss from Continuing Operations $-86M (+85% y/y); Adjusted EBITDA $22M (-69% y/y); Guidance: Revenue guidance $2.81B-$2.92B (+49% YoY midpoint); GAAP Net Income $0-$20M (first-ever profitabilitearningsopen
Figures in the filing · each found in the filing text
| Consolidated Gross Profit · FY2025 | $356M | -2% y/y |
| Net Loss from Continuing Operations · FY2025 | $-86M | +85% y/y |
| Adjusted EBITDA · FY2025 | $22M | -69% y/y |
| Average Medicare Advantage Membership · Insurance · FY2025 | 107,084 | +33% y/y |
| Insurance Revenue · Insurance · FY2025 | $1.89B | +41% y/y |
| Insurance BER · Insurance · FY2025 | 90.9% | |
| Total Cash, Cash Equivalents, and Investments · FY2025 | $320M | -27% y/y |
Guidance
Revenue guidance $2.81B-$2.92B (+49% YoY midpoint); GAAP Net Income $0-$20M (first-ever profitability)
Strong guidance for 2026 with significant revenue growth, first GAAP net income profitability, and improving cohort economics.
Risks flagged
Insurance BER increased to 90.9% from 81.2% due to higher medical claims incurred.
“Insurance BER 90.9%, up 970 bps year-over-year. Normalized Insurance BER 91.5%, up 730 bps.”
Cash and investments decreased 26.9% YoY, indicating cash burn.
“Total cash, cash equivalents, and investments $319.9 million, down 26.9% year-over-year.”
14 Jan 20268-K · 7.01Medicare Advantage membership growth (AEP) 53; HEDIS quality score 4.72; Guidance: FY26 GAAP Net Income profitability; sustained Adjusted EBITDA profitabilityopen
Figures in the filing · each found in the filing text
| Medicare Advantage membership growth (AEP) · Q1-2026 | 53.0% | |
| HEDIS quality score · PPO · FY2026 | $4.72 |
Guidance
FY26 GAAP Net Income profitability; sustained Adjusted EBITDA profitability
Company raises guidance by targeting GAAP Net Income profitability in FY26, supported by strong AEP growth and clinical quality leadership.
Risks flagged
Medical cost trend and cohort economics could pressure margins if utilization rises unexpectedly.
“Strong medical cost trend & cohort economics, gaining SG&A leverage” · word for word
10 Dec 20258-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
No specific financial data; boilerplate risk factors.
12 Nov 20258-K · 7.01Underlying incurred Part C medical cost trend (excluding pharmacy) 4; Guidance: Expect notable improvement in both new and returning cohorts contribution profit in 2026open
Figures in the filing · each found in the filing text
| Underlying incurred Part C medical cost trend (excluding pharmacy) · Q3-2025 | 4.0% |
Guidance
Expect notable improvement in both new and returning cohorts contribution profit in 2026
Management confident in 2026 profitability expansion due to star rating, rate update, and member cohort maturation.
Risks flagged
Medical cost pressures from new member cohorts could persist if retention or care management does not improve.
“We saw elevated utilization across all cohorts, consistent with broader industry trends, with pressures more pronounced within new member cohorts.” · word for word
7 Nov 202510-QClover Health reported Q3 2025 results with strong membership growth but significantly higher medical cost ratio and lower adjusted EBITDA, alongside a CMS star rating downgrade for its PPO plans.earningsopen
Figures in the filing · each found in the filing text
| Insurance members at period end · Insurance · Q3-2025 | 109,226 | +35% y/y |
| Premiums earned, net · Insurance · Q3-2025 | $479M | +49% y/y |
| Benefits expense ratio, gross · Insurance · Q3-2025 | 93.5% | |
| Normalized benefits expense ratio, gross · Insurance · Q3-2025 | 92.4% | |
| Adjusted EBITDA · Q3-2025 | $2M | -89% y/y |
| Adjusted Net income from continuing operations · Q3-2025 | $2M | -91% y/y |
| Cash, cash equivalents, and investments · 2025-09-30 | $396M |
Risks flagged
Star Rating Downgrade Risk
“CMS has decreased the Star rating of its PPO Medicare Advantage plans to 3.5 Stars for 2026, which will affect payment year 2027.” · word for word
Medical Cost Ratio Deterioration
“Benefits expense ratio, gross 93.5 % ... 82.8 %” · word for word
4 Nov 20258-K · 7.01Total revenues $497M (+50% y/y); Insurance revenue $479M (+48% y/y); Net loss from continuing operations $-24M; Guidance: Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER raised to 90-91% from 88.5-89.5%.open
Figures in the filing · each found in the filing text
| Total revenues · Q3-2025 | $497M | +50% y/y |
| Insurance revenue · Insurance · Q3-2025 | $479M | +49% y/y |
| Net loss from continuing operations · Q3-2025 | $-24M | |
| Adjusted EBITDA · Q3-2025 | $2M | -89% y/y |
| Average Medicare Advantage membership · Medicare Advantage · Q3-2025 | 108,231 | +34% y/y |
| Insurance BER · Insurance · Q3-2025 | 93.5% | |
| Adjusted SG&A · Q3-2025 | $71M | +15% y/y |
| Total cash, cash equivalents, and investments · Q3-2025 | $396M | -26% y/y |
Guidance
Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER raised to 90-91% from 88.5-89.5%.
Revenue and membership growth strong, but margin pressure from new member mix and utilization leads to significant guidance cut for profitability. FY2026 outlook positive with star rating and rate tailwinds.
Risks flagged
Guidance cut reflects higher-than-expected new member mix and elevated utilization pressuring margins.
“Adjusted EBITDA guidance cut from $50-70M to $15-30M; Insurance BER guidance raised to 90-91%.”
Cash burn; cash reserves down 25.5% YoY to $395.9M.
“Total cash, cash equivalents, and investments $395.9M vs $531.4M.”
Dependence on CMS rate updates and star ratings for profitability improvement in 2026.
“FY2026 outlook relies on 4.0 Star payment year and favorable CMS rate update.”
31 Oct 20258-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Board vacancy may reduce governance oversight temporarily.
“Board will continue to operate with two vacant seats” · word for word
Clover Health Investments, Corp. — questions
- What did Clover Health Investments, Corp. file recently?
- 23 SEC filings in the last 12 months. Latest: 8-K on 2026-10-09 — CMS awarded Clover's PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, enabling year-round enrollment and higher payments; core HEDIS score remains 4.82/5, ranking #1 among non-SNP PPO plans.
Every figure on this page comes from Clover Health Investments, Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.